Summary

The efficacy and safety of the antiresorptive agent denosumab on bone mineral density and fracture rates were assessed in an open-label extension, crossover trial of the original 3-year, randomized, placebo-controlled Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months study. [FREEDOM; NCT00089791; Cummings SR et al. N Engl J Med 2009].